Compare FedEx Corporation (FDX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Summit Therapeutics Inc — how do they compare? FedEx Corporation trades at $317.05 (market cap $74.78B), while Summit Therapeutics Inc trades at $14.36 (market cap $11.70B). The key difference: FedEx Corporation is far larger — about 6.4× Summit Therapeutics Inc's market cap, and FedEx Corporation pays a 1.56% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FDX | SMMT | |
|---|---|---|
Market Cap | $74.78B | $11.70B |
Sector | Industrials | Health |
52-Week High | $338.75 | $29.32 |
52-Week Low | $174.81 | $13.05 |
Enterprise Value | $104.42B | $11.12B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $313.66, down slightly by 0.03% on the day, with a bearish technical signal from moving averages and ADX indicators. The company reported revenue of $87.93B for 2025, with a net income margin of 4.68%, and has beaten EPS estimates in recent quarters. Recent corporate actions include a dividend payment and a $1.4B sale of its supply chain unit to CMA CGM, aimed at streamlining operations.
The outlook for FDX is mixed; analyst consensus is bullish with a $360.27 price target, but technicals and margin pressures pose risks. Investment opportunities lie in cost-cutting initiatives and steady revenue growth, while risks include competitive threats from Amazon and soft shipping demand. The stock's valuation appears reasonable with a P/E of 16.9.
Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.
SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
